Minimally invasive Pharmacokinetic and Pharmacodynamic Technologies in hypothesis-testing clinical trials of innovative therapies

Journal of the National Cancer Institute

Volumn 98, Issue 9, 2006, Pages 580-598

  Workman, Paul ^a   Aboagye, Eric O ^b   Chung, Yuen Li ^c   Griffiths, John R ^c   Hart, Rachel ^c   Leach, Martin O ^d   Maxwell, Ross J ^e   McSheehy, Paul M J ^f   Price, Pat M ^c   Zweit, Jamal ^g  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANNEXIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CARBON 11; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; FIALURIDINE; FLUCYTOSINE; FLUORINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOLINIUM PENTETATE; GEMCITABINE; IFOSFAMIDE; IODINE 124; IPROPLATIN; METHIONINE; N ACETYLCOLCHINOL PHOSPHATE; PHOSPHORUS 31; PROTON; TEMOZOLOMIDE; THYMIDINE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG; VASCULOTROPIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; APOPTOSIS; BLOOD FLOWMETRY; BLOOD VOLUME; BRAIN CANCER; BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIFFUSION WEIGHTED IMAGING; DOPPLER ECHOGRAPHY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFORMATION; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; DRUG TUMOR LEVEL; DRUG UPTAKE; ECHOGRAPHY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE UTILIZATION; HUMAN; HYPOTHESIS; HYPOXIA; INTERMETHOD COMPARISON; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL ETHICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PH; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SENSITIVITY AND SPECIFICITY; TECHNOLOGY; TISSUE PERFUSION; TREATMENT OUTCOME; TUMOR CELL; UNITED KINGDOM; UTERINE CERVIX CANCER; VOLUMETRY; BLOOD FLOW VELOCITY; CELL HYPOXIA; METABOLISM; METHODOLOGY; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIOGRAPHY; SCINTISCANNING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; CELL HYPOXIA; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 33646457229     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj162     Document Type: Review

References (178)

1. Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 1999;35:2010-30.
2. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-73.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
4. Kaelin WG. Choosing anticancer drug targets in the post-genomic era. J Clin Invest 1999;104:1503-6.
5. Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer: Targets, technologies and molecular chaperones. Cancer Chemother Pharmacol 2003;52 Suppl 1:S45-56.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
8. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4324-49.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
10. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
11. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
13. Workman P, Kaye SB. Translating basic cancer research into new cancer therapeutics. Trends Mol Med 2002;8(4 Suppl):S1-S8.
14. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signalling molecules and the cancer cell environment: Challenges for drug development? J Natl Cancer Inst 1999;91:1281-7.
15. Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002;38:2189-93.
16. Workman P. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
17. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: Unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003;2:131-8.
18. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2:566-80.
19. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004;10:3885-96.
20. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 2004;96:990-7.
21. Newell DR, Searle KM, Westwood NB, Burtles SS, on behalf of the Cancer Research UK Phase I/II Clinical Trials Committee. Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer 2003;89:437-54.
22. Collins JM. Functional imaging in phase I studies: Decorations or decision making? J Clin Oncol 2003;21:2807-9.
23. Husband JE, Reznek RH. Imaging in oncology. Oxford (U.K.): Isis Medical Media; 1998.
24. Dixon AK. The appropriate use of computed tomography. Br J Radiol 1997;70:S98-S105.
25. MacVicar D, Husband JE. Assessment of response following treatment for malignant disease. Br J Radiol 1997;70:S41-S49.
26. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981;47:207-14.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
28. Miles KE. Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 1991;64:409-12.
29. Whittingham TA. New and future developments in ultrasonic imaging. Br J Radiol 1997;70:S119-S132.
30. Fenster A, Downey DB, Cardinal HN. Three-dimensional ultrasound imaging. Phys Med Biol 2001;46:R67-R99.
31. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma-measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology 1994;190:825-30.
32. Kedar RP, Cosgrove D, McCready VR, Bamber JC, Carter ER. Microbubble contrast agent for color Doppler US: Effect on breast masses. Radiology 1996;198:679-86.
33. Blomley MJ, Eckersley RJ. Functional ultrasound methods in oncological imaging. Eur J Cancer 2002;38:2108-15.
34. Dayton PA, Ferrara KW. Targeted imaging using ultrasound. J Magn Reson Imaging 2002;16:362-77.
35. Padhani AR. Functional MRI for anticancer therapy assessment. Eur J Cancer 2002;38:2116-27.
36. Schneider G, Uder M. Contrast enhanced magnetic resonance body imaging 5. Top Magn Reson Imaging 2003;14:403-25.
37. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media; status report. Eur J Radiol 2000;34:148-55.
38. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, et al. Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004;20:138-44.
39. Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2003;2:419-26.
40. Degani H, Chetrit-Dadani M, Bogin L, Furman-Haran E. Magnetic resonance imaging of tumour vasculature. Thromb Haemost 2003;89:25-33.
41. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
42. Taylor JS, Reddick WE. Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Adv Drug Deliv Rev 2000;41:91-110.
43. Parker GJM, Suckling J, Tanner SF, Padhani AR, Husband JE, Leach MO. MRIW: Parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. RadioGraphics 1998;18:497-506.
44. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002;15:154-63.
45. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using extravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. Magn Reson Med 1996;36:726-36.
46. d'Arcy JA, Collins DJ, Rowland IJ, Padhani AR, Leach MO. Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. NMR Biomed 2002;15:174-83.
47. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 2005;92:1599-610.
48. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: Recommendations for appropriate methodology for clinical trials. Br J Radiol 2003;76:S87-91.
49. Bentzen L, Vestergaard-Poulsen P, Nielsen T, Overgaard J, Bjornerud A, Briley-Saebo K, et al. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys 2005;15:1208-15.
50. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized MRI contract agents. Curr Pharm Biotechnol 2004;5:539-49.
51. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 2001;218:562-9.
52. Nguyen BC, Stanford W, Thompson BH, Rossi NP, Kernstine KH, Kern JA, et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging 1999;10:468-73.
53. Preda A, Novikov V, Moglich M, Turetschek K, Shames DM, Brasch RC, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004;20:865-73.
54. Parker GJ, Suckling J, Tanner SF, Padhani AR, Revell PB, Husband JE, et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997;7:564-74.
55. Padhani AR. Dynamic contrast-enhanced MRI studies in human tumours. Br J Radiol 1999;72:427-31.
56. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-6.
57. Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997;7:461-4.
58. Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999;10: 277-85.
59. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic-contrast enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
60. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
61. Evelhoch JL, LoRusso PM, He ZQ, DelProposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-7.
62. Padhani AR, MacVicar DA, Gapinksi CJ, Revell P, Parker GJM, Suckling J, et al. Effects of androgen deprivation treatment on prostate morphology and vascular permeability evaluated by magnetic resonance imaging. Radiology 2001;218:365-74.
63. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002;15:154-63.
64. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 2003;21:3897-9.
65. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63:2723-7.
66. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000;6:351-5.
67. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18:321-5.
68. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219: 316-33.
69. Schellenberger EA, Hogemann D, Josephson L, Weissleder R. Annexin V-CLIO: A nanoparticle for detecting apoptosis by MRI. Acad Radiol 2002; 9 Suppl 2:S310-1.
70. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999;1:113-7.
71. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360:307-8.
72. Gadian DG. NMR and its applications to living systems. 2nd ed. Oxford (U.K.): Oxford Science Publications; 1995.
73. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451-63.
74. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-203.
75. Mahon MM, Williams AD, Soutter WP, Cox IJ, McIndoe GA, Coutts GA, et al. 1H magnetic resonance spectroscopy of invasive cervical cancer: An in vivo study with ex vivo corroboration. NMR Biomed 2004;17:1-9.
76. Griffiths JR, Tate AR, Howe FA, Stubbs M. Magnetic resonance spectroscopy of cancer practicalities of multi-centre trials and early results in non-Hodgkins lymphoma. Eur J Cancer 2002;38:2085-93.
77. 31P measurements of response to treatment. NMR Biomed 1998;11: 314-40.
78. Ronen SM, Leach MO. Imaging biochemistry: Applications to breast cancer. Breast Cancer Res 2001;3:36-40.
79. Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TAD, Al-Saffar NM, et al. Magnetic resonance detects metabolic changes associated with chemotherapy induced apoptosis. Br J Cancer 1999;80:1035-41.
80. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis. Nat Med 1999;5:1323-7.
81. 1H NMR spectroscopy in vivo, ex vivo, and in vitro. J Biol Chem 2003;278:45915-23.
82. Murphy PS, Dzik-Jurasz A, Baustert I, Leach MO, Rowland IJ. Choline signal correlates with vascular permeability in human gliomas. Proc Int Soc Magn Reson Med 2000;8:393.
83. Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90:781-6.
84. 1H MR spectroscopy in extracranial lymphoma and germ cell tumors. Br J Radiol 2002;75:959-66.
85. Aboagye EO, Kelson AB, Tracy M, Workman P. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): A non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des 1998;13:703-30.
86. Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, et al. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 2002;8:2323-35.
87. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, et al. A phase I study of SR-4554 via intravenous administration for non-invasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res 2003;9:5101-12.
88. 19F magnetic resonance spectroscopy in vivo predict response of murine RIF-1 tumours to 5-fluorouracil. Cancer Res 2000;60:2122-7.
89. 13C nuclear magnetic resonance studies. Breast Cancer Res Treat 1997;43:15-25.
90. McSheehy PMJ. On the role of MRS in drug development. NMR Biomed 1999;12:402-3.
91. Robinson SP, Barton SJ, McSheehy PMJ, Griffiths JR. Nuclear magnetic resonance spectroscopy of cancer. Br J Radiol 1997;70:S60-S69.
92. 2) breathing in rats after 5FU treatment. Acta Oncol 2001;40:609-14.
93. 19F-MRS of 5-fluorouracil in pharmacokinetics and pharmacodynamics. NMR Biomed 1998;11: 380-7.
94. Findlay MPN, Leach MO. In vivo monitoring of fluoropyrimidine metabolites: Magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. Anticancer Drugs 1994;5:260-80.
95. 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. Cancer Res 2003;63:7609-12.
96. 31P MRS: pulse-and-acquire, decoupling and polarization transfer. Magn Res Med 2000;44: 180-4.
97. 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. Anticancer Drugs 2004;15:229-33.
98. Greco O, Dachs GU. Gene directed enzymes/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001;187: 22-36.
99. He Q, Bhujwalla ZM, Maxwell RJ, Griffiths JR, Glickson JD. Proton NMR observation of the antineoplastic agent iproplatin in vivo by selective multiple quantum coherence transfer (Sel-MQC). Magn Reson Med 1995;33:414-6.
100. 13C labelled anticancer agent temozolomide detected in vivo by selective cross polarization transfer. Magn Reson Med 1995;34:338-42.
101. 19F-MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil. Magn Reson Med 2000;44:516-20.
102. Cherubini A, Payne GS, Leach MO, Bifone A. Hyperpolarising C-13 for NMR studies using laser-polarised Xe-129: SPINOE vs thermal mixing. Chem Phys Lett 2003;371:640-4.
103. Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TA, Al-Saffar NM, et al. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer 1999;80:1035-41.
104. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001;84:691-6.
105. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signalling inhibition. Cancer Res 2005;65:3356-63.
106. Chung Y-L, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the Hsp90 inhibitor 17-allylamino,17-demethoxygeldanamycin in human colon cancer Models. J Natl Cancer Inst 2003;95:1624-33.
107. Leach MO, Arnold D, Brown TR, Charles HC, de Certaines JD, Evelhoch JL, et al. International workshop on Standardization in Clinical Magentic Resonance Spectroscopy Measurements: Proceedings and recommendations. Acad Radiol 1994;1:171-86.
108. Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. Molecular imaging with endogenous substances. Proc Natl Acad Sci USA 2003;100:10435-9.
109. Lanza GM, Winter P, Caruthers S, Schmeider A, Crowder K, Morawski A, et al. Novel paramagnetic contrast agents for moleculare imaging and targeted drug delivery. Curr Pharm Biotechnol 2004;5:495-507.
110. Saleem A, Aboagye EO, Price PM. In vivo monitoring of drugs using radiotracer techniques. Adv Drug Deliv Rev 2000;41:21-39.
111. Gupta N, Price PM, Aboagye EO. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 2002;38:2094-107.
112. Saleem A, Harte RJ, Matthews JC, Osman S, Brown GD, Bleehen N, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA; XR5000) in patients by positron emission tomography. J Clin Oncol 2001;19:1421-9.
113. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug action. Lancet 2000;355:2125-31.
114. Brock CS, Matthews JC, Brown G, Luthra SK, Brady F, Newlands ES, et al. The kinetic behavior of temozolomide in man [abstract]. Proc Am Soc Clin Oncol 1996;15:475.
115. 13N]Cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumours. J Nucl Med 1987;28:1844-52.
116. 11C-labelled BCNU and SarCNU in gliomas studied by PET. J Neurooncol 1991;10:45-55.
117. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging 1997;21:332-6.
118. Saleem A, Harte RJH, Matthews C, Osman S, Brady F, Luthra SK, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 2001;19:1421-9.
119. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, et al. Metabolic activation of temozolamide measured in vivo using positron emission tomography. Cancer Res 2003;63:2409-15.
120. Tavitian B, Terrazzino S, Kuhnast B, Marzabal S, Stettler O, Dolle F, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 1998;4:467-71.
121. van Oosterom AT, Judson I, Verweij J, Strobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase 1 study. Lancet 2001;358:1421-3.
122. 18F]-fluorodeoxyglucose and positron emission tomography: Review of the technique and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-82.
123. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001;33:451-5.
124. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999; 59:615-21.
125. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-8.
126. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 1992;52:1592-7.
127. Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1984;1:131-4.
128. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
129. 11C]methionine. Int J Radiat Oncol Biol Phys 1995;32:787-94.
130. 18F-fluoro-l-dopa, a new tumor imaging agent: Investigation of transport mechanism in vitro. J Nucl Med 2004;45:2116-22.
131. Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wislon V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;22:1389-98.
132. 11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003;95:675-82.
133. 124I]Iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 2002;62:5912-9.
134. Jayson GC, Zweit J, Mulatero C, Julyan P, Ranson M, Broughton L, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
135. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Lasron SM. Imaging the pharmacodynamics of Her2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701-6.
136. 18F]fluoro-17β-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996;2:933-9.
137. 18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
138. 18F]fluoroetanidazole as a new marker for imaging tumor hypoxia with positron emission tomography. Br J Cancer 2004;90:2232-42.
139. 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-50.
140. 124I-annexin and PET. Nucl Med Biol 2005;32:395-402.
141. Collingridge DR, Glaser M, Osman S, Barthel H, Hutchinson OC, Luthra SK, et al. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003;89:1327-33.
142. van de Weile C, Lahorte C, Vermeersch H, Loose D, Mervillie K, Steinmetz ND, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol 2003;21:3483-7.
143. Dekker BA, Keen HG, Shaw D, Disley L, Hastings D, Hadfield J, et al. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. Nucl Med Biol 2005;32:403-13.
144. Dekker BA, Keen HG, Lyons S, Disley L, Hastings H, Reader AJ, et al. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl Med Biol 2005;32:241-52.
145. 18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability and radiation dose estimates. Bioconjug Chem 2004;15:61-9.
146. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004;6:350-9.
147. Tjuvajev JG, April N, Oku T, Sasajima T, Miyagawa T, Joshi R, et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 1998;58:4333-41.
148. Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 2000;97: 2785-90.
149. MacLaren DC, Gambhir SS, Satyamurthy N, Barrio JR, Sharfstein S, Toyokuni T, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999;6:785-91.
150. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine N, Vassaux G. Adeno-virus biodistribution and non-invasive imaging of gene expression in vivo by positron emission tomography using the human sodium/iodide symporter as a reporter gene. Hum Gene Ther 2002;13:1723-35.
151. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001;358:727-9.
152. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, et al. A new in vivo method to study P-glycoprotein transport in tumours and the blood-brain barrier. Cancer Res 1999;59:2411-6.
153. Goerres GW, Kamel E, Seifert B, Burger C, Buck A, Hany TF, et al. Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med 2002;43:1469-75.
154. Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, et al. A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med 2000;41:706-11.
155. Aboagye EO. PET imaging of small animals in anticancer drug development. Mol Imaging Biol 2005;7:53-8.
156. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, et al. Cancer Research UK procedures in manufacture and toxicology of radio-tracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 2002;86:1052-6.
157. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
158. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop. Control Clin Trials 2001;22:485-502.
159. De Meyer G, Shapiro F. Biomarker development: The road to clinical utility. Curr Drug Discov 2003;12:23-7.
160. Atkinson AJ. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
161. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989;8:431-40.
162. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER). Draft guidance for industry, investigators and reviewers. Exploratory IND studies. Available at: http://www.fda.gov/cder/guidance/index.htm. [Last accessed: April 4, 2006.]
163. Gross S, Piwnica-Worms D. Spying on cancer: Molecular imaging in vivo with genetically encoded reporters. Cancer Cell 2005;7:5-15.
164. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002;8:757-60.
165. Gelovani Tjuvajev J, Blasberg RG. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 2003;3:327-32.
166. Aboagye EO, Saleem A, Cunningham V, Osman S, Price P. Extraction of 5-fluorouracil by tumour and liver: A non-invasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001;61:4937-41.
167. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38 Suppl 5:S60-5.
168. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhom-Crews JM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998;4:1334-6.
169. 18F-FDG. J Nucl Med 2003;44:1426-31.
170. 68Germanium Attenuation Correction. Mol Imaging Biol 2002;4:399-309.
171. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22.
172. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30.
173. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
174. Baselga J, Rischin D, Ranson M, Calvert H, Raymond F, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20: 4292-302.
175. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
176. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;1:3578-88.
177. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
178. Roberts TG, Chabner BA. Beyond fast track for drug approvals. N Engl J Med 2004;351:501-5.